Scientists from the University of Tokusima recently tested the multi-tyrosine kinase E7080 inhibitor to see the efficacy of this important inhibitor against pleural malignant mesothelioma cells in mice, which were implemented with three different human pleural mesothelioma cell lines.
The results of their study show that the number of the malignant pleural mesothelioma cells in the tumor of the mice, decreased shortly after the inhibitor was administrated.
Those three different human malignant pleural mesothelioma used by the specialists at the University of Tokusima, were: MSTO 211H, NCO-H290 and Y-MESO-14.
Scientists from the university said that the efficacy of the inhibitor is obvious; the utility of the inhibitor demonstrated a potential new strategy involving vascular endothelial growth factors for treating malignant pleural mesothelioma.
The journal of Clinical Cancer Research published an article in which they have mentioned the importance of the inhibitor E7080 for curing pleural mesothelioma and its main role is to slow down the progression of all three malignant pleural mesothelioma cell lines.
Mesothelioma is a disease, a deadly disease, which is caused by exposure to asbestos. It is a rare type of cancer and in most cases, if diagnosed late and left untreated it causes death of the patients. People who have worked with materials and products containing asbestos were exposed to mesothelioma cancer. Most of the mesothelioma patients do not develop cancer symptoms until the disease got to an advanced stage.
For mesothelioma cancer patients, doctors and scientist have developed clinical trials and studies, to find a cure for mesothelioma. Experimental treatments are developed on the basis of using the inhibitors of growth factors receptor, which represents a potential therapeutic option, for mesothelioma cancer patients.
Best results in mesothelioma cancer cure can be obtained if the disease is diagnosed in time. People who have reached an advanced stage of the disease have less chances to be cured.